| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | GATEWAY BIOTECHNOLOGY, INC | 1154 N WARSON RD | SAINT LOUIS | MO | 63132-1809 | SAINT LOUIS | USA | R44DC018759 | Targeting multiple signaling pathways for tinnitus prevention and treatment | 000 | 2 | NIH | 1/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $473,509 ) |
| | 2023 | 2023 | GATEWAY BIOTECHNOLOGY INC | 4209 STATE ROUTE 44 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R42AG078721 | Developing a clinical diagnostic tool for age-related cochlear synaptopathy. | 000 | 2 | NIH | 9/14/2023 | $473,509 |
|
| Issue Date FY: 2022 ( Subtotal = $555,803 ) |
| | 2022 | 2022 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R42AG078721 | Developing a clinical diagnostic tool for age-related cochlear synaptopathy. | 000 | 1 | NIH | 9/23/2022 | $555,803 |
| | 2022 | 2018 | GATEWAY BIOTECHNOLOGY INC | 4209 STATE ROUTE 44 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 000 | 1 | NIH | 5/12/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,207,345 ) |
| | 2021 | 2021 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R44DC018759 | Targeting multiple signaling pathways for tinnitus prevention and treatment | 001 | 2 | NIH | 6/15/2021 | $1,207,345 |
| | 2021 | 2020 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R44DC018759 | Targeting multiple signaling pathways for tinnitus prevention and treatment | 000 | 1 | NIH | 6/8/2021 | $0 |
| | 2021 | 2019 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 001 | 1 | NIH | 3/15/2021 | $0 |
| | 2021 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 000 | 1 | NIH | 3/9/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $972,613 ) |
| | 2020 | 2020 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R44DC018759 | Targeting multiple signaling pathways for tinnitus prevention and treatment | 000 | 1 | NIH | 6/18/2020 | $972,613 |
| | 2020 | 2019 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017108 | Developing a Nutraceutical Product against Ototoxicity | 000 | 1 | NIH | 5/7/2020 | $0 |
| | 2020 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R43DC017418 | Developing a new AAV-based tool for targeted gene therapy against hearing loss | 000 | 1 | NIH | 11/25/2019 | $0 |
| | 2020 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 000 | 1 | NIH | 2/26/2020 | $0 |
| | 2020 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 001 | 1 | NIH | 4/3/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $305,055 ) |
| | 2019 | 2019 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017108 | Developing a Nutraceutical Product against Ototoxicity | 000 | 1 | NIH | 11/19/2018 | $205,183 |
| | 2019 | 2019 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 001 | 1 | NIH | 9/4/2019 | $99,872 |
| | 2019 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 000 | 1 | NIH | 9/4/2019 | $0 |
| | 2019 | 2017 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC016842 | Developing a Nutraceutical Product against Noise-Induce Hearing Loss | 000 | 1 | NIH | 2/20/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $449,400 ) |
| | 2018 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC017406 | An unique patient population for clinical trials against noise-induced hearing loss | 000 | 1 | NIH | 8/15/2018 | $224,700 |
| | 2018 | 2018 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R43DC017418 | Developing a new AAV-based tool for targeted gene therapy against hearing loss | 000 | 1 | NIH | 7/25/2018 | $224,700 |
| | 2018 | 2017 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC016575 | Develop a new cisplatin-based drug combination with reduced ototoxicity | 000 | 1 | NIH | 3/7/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $449,400 ) |
| | 2017 | 2017 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC016575 | Develop a new cisplatin-based drug combination with reduced ototoxicity | 000 | 1 | NIH | 7/5/2017 | $224,700 |
| | 2017 | 2017 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41DC016842 | Developing a Nutraceutical Product against Noise-Induce Hearing Loss | 000 | 1 | NIH | 9/18/2017 | $224,700 |
| | 2017 | 2016 | GATEWAY BIOTECHNOLOGY INC. | 134 SHAW DR | KENT | OH | 44240-7399 | PORTAGE | USA | R41AT008922 | Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss | 000 | 1 | NIH | 12/19/2016 | $0 |
| | 2017 | 2016 | GATEWAY BIOTECHNOLOGY INC. | 4209 STATE ROUTE 44, SUITE D-148 | ROOTSTOWN | OH | 44272-9698 | PORTAGE | USA | R41AT008922 | Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss | 001 | 1 | NIH | 9/20/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,701 ) |
| | 2016 | 2016 | GATEWAY BIOTECHNOLOGY INC | 6909 WASHINGTON AVENUE | SAINT LOUIS | MO | 63130 | SAINT LOUIS | USA | R41AT008922 | Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss | 000 | 1 | NIH | 4/15/2016 | $224,701 |
|
| Issue Date FY: 2014 ( Subtotal = $224,700 ) |
| | 2014 | 2014 | GATEWAY BIOTECHNOLOGY INC | 6909 WASHINGTON AVENUE | SAINT LOUIS | MO | 63130 | SAINT LOUIS | USA | R43DC013432 | A new two-drug combination therapy for noise-induced hearing loss | 000 | 1 | NIH | 4/29/2014 | $224,700 |
|
|
